Madrigal Pharmaceuticals (MDGL) Current Assets (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Current Assets data on file, last reported at $1.2 billion in Q1 2026.

• Quarterly Current Assets rose 19.67% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 19.67% YoY) and the FY2025 annual result came in at $1.2 billion, up 20.61% from the prior year.
• Current Assets fell to $1.2 billion in Q1 2026 per MDGL's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Current Assets topped out at $1.3 billion in Q3 2025 and bottomed at $157.1 million in Q3 2022.
• The 5-year median for Current Assets is $988.0 million (2025), against an average of $734.6 million.
• The widest annual swing landed in 2022, when Current Assets plunged 48.14%; it then jumped 351.72% in 2024.
• Tracing MDGL's Current Assets over 5 years: stood at $361.4 million in 2022, then soared by 76.35% to $637.3 million in 2023, then surged by 62.08% to $1.0 billion in 2024, then advanced by 20.61% to $1.2 billion in 2025, then decreased by 5.09% to $1.2 billion in 2026.
• Per Business Quant, the three latest MDGL Current Assets figures stand at $1.2 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.3 billion (Q3 2025).

Peer Comparison